Stockreport

Daiichi Sankyo and MSD's ADC improves progression-free survival in NSCLC trial [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Discovered by Daiichi Sankyo, patritumab deruxtecan is jointly developed by Daiichi Sankyo and MSD. Daiichi Sankyo research and development global head Ken Takeshita [Read more]